[1]
Ajila, V. et al. 2015. Human Papilloma Virus Associated Squamous Cell Carcinoma of the Head and Neck. Journal of Sexually Transmitted Diseases. 2015, (2015), 1–5. DOI:https://doi.org/10.1155/2015/791024.
[2]
Barrett, D.M. et al. 2015. Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street. The Journal of Immunology. 195, 3 (Aug. 2015), 755–761. DOI:https://doi.org/10.4049/jimmunol.1500751.
[3]
Ecker, D.M. et al. 2015. The therapeutic monoclonal antibody market. mAbs. 7, 1 (Jan. 2015), 9–14. DOI:https://doi.org/10.4161/19420862.2015.989042.
[4]
Gill, S. and June, C.H. 2015. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunological Reviews. 263, 1 (Jan. 2015), 68–89. DOI:https://doi.org/10.1111/imr.12243.
[5]
Grupp, S.A. et al. 2013. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia. New England Journal of Medicine. 368, 16 (Apr. 2013), 1509–1518. DOI:https://doi.org/10.1056/NEJMoa1215134.
[6]
Hanahan, D. and Weinberg, R.A. 2000. The Hallmarks of Cancer. Cell. 100, 1 (Jan. 2000), 57–70. DOI:https://doi.org/10.1016/S0092-8674(00)81683-9.
[7]
zur Hausen, H. 2009. Papillomaviruses in the causation of human cancers — a brief historical account. Virology. 384, 2 (Feb. 2009), 260–265. DOI:https://doi.org/10.1016/j.virol.2008.11.046.
[8]
Hodi, F.S. et al. 2010. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine. 363, 8 (Aug. 2010), 711–723. DOI:https://doi.org/10.1056/NEJMoa1003466.
[9]
Jeggo, P.A. et al. 2015. DNA repair, genome stability and cancer: a historical perspective. Nature Reviews Cancer. 16, 1 (Dec. 2015), 35–42. DOI:https://doi.org/10.1038/nrc.2015.4.
[10]
Kaufman, H.L. et al. 2015. Oncolytic viruses: a new class of immunotherapy drugs. Nature Reviews Drug Discovery. 14, 9 (Sep. 2015), 642–662. DOI:https://doi.org/10.1038/nrd4663.
[11]
Klebanoff, C.A. et al. 2016. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nature Medicine. 22, 1 (Jan. 2016), 26–36. DOI:https://doi.org/10.1038/nm.4015.
[12]
Koebel, C.M. et al. 2007. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 450, 7171 (Dec. 2007), 903–907. DOI:https://doi.org/10.1038/nature06309.
[13]
Larson, C. et al. 2015. Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget. 6, 24 (Aug. 2015). DOI:https://doi.org/10.18632/oncotarget.5116.
[14]
Lazebnik, Y. 2010. What are the hallmarks of cancer? Nature Reviews Cancer. 10, 4 (Apr. 2010), 232–233. DOI:https://doi.org/10.1038/nrc2827.
[15]
Lingyun Geng 2015. Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments. International Journal of Clinical and Experimental Medicine. 8, 9 (2015).
[16]
de Martel, C. et al. 2012. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. The Lancet Oncology. 13, 6 (Jun. 2012), 607–615. DOI:https://doi.org/10.1016/S1470-2045(12)70137-7.
[17]
Matsuoka, M. and Jeang, K.-T. 2011. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene. 30, 12 (Mar. 2011), 1379–1389. DOI:https://doi.org/10.1038/onc.2010.537.
[18]
Morris, E.C. and Stauss, H.J. 2016. Optimizing T-cell receptor gene therapy for hematologic malignancies. Blood. 127, 26 (Jun. 2016), 3305–3311. DOI:https://doi.org/10.1182/blood-2015-11-629071.
[19]
Palucka, K. and Banchereau, J. 2012. Cancer immunotherapy via dendritic cells. Nature Reviews Cancer. 12, 4 (Mar. 2012), 265–277. DOI:https://doi.org/10.1038/nrc3258.
[20]
Pierangeli, A. et al. 2015. Immunodeficiency-associated viral oncogenesis. Clinical Microbiology and Infection. 21, 11 (Nov. 2015), 975–983. DOI:https://doi.org/10.1016/j.cmi.2015.07.009.
[21]
Reichert, J.M. 2016. Antibodies to watch in 2016. mAbs. 8, 2 (Feb. 2016), 197–204. DOI:https://doi.org/10.1080/19420862.2015.1125583.
[22]
Reichert, J.M. 2017. Antibodies to watch in 2017. mAbs. 9, 2 (Feb. 2017), 167–181. DOI:https://doi.org/10.1080/19420862.2016.1269580.
[23]
Reichert, J.M. 2012. Marketed therapeutic antibodies compendium. mAbs. 4, 3 (May 2012), 413–415. DOI:https://doi.org/10.4161/mabs.19931.
[24]
Restifo, N.P. et al. 2012. Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Reviews Immunology. 12, 4 (Mar. 2012), 269–281. DOI:https://doi.org/10.1038/nri3191.
[25]
Robbins, P.F. et al. 2011. Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. Journal of Clinical Oncology. 29, 7 (Mar. 2011), 917–924. DOI:https://doi.org/10.1200/JCO.2010.32.2537.
[26]
Robert D. Schreiber, Lloyd J. Old and Mark J. Smyth 2011. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion. Science. 331, 6024 (2011), 1565–1570.
[27]
Roos, W.P. et al. 2015. DNA damage and the balance between survival and death in cancer biology. Nature Reviews Cancer. 16, 1 (Dec. 2015), 20–33. DOI:https://doi.org/10.1038/nrc.2015.2.
[28]
Russell, S.J. et al. 2012. Oncolytic virotherapy. Nature Biotechnology. 30, 7 (Jul. 2012), 658–670. DOI:https://doi.org/10.1038/nbt.2287.
[29]
Schinzari, V. et al. 2015. Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. Clinical Microbiology and Infection. 21, 11 (Nov. 2015), 969–974. DOI:https://doi.org/10.1016/j.cmi.2015.06.026.
[30]
Schumacher, T.N. and Schreiber, R.D. 2015. Neoantigens in cancer immunotherapy. Science. 348, 6230 (Apr. 2015), 69–74. DOI:https://doi.org/10.1126/science.aaa4971.
[31]
Shankaran, V. et al. 2001. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 410, 6832 (Apr. 2001), 1107–1111. DOI:https://doi.org/10.1038/35074122.
[32]
Spurgeon, M.E. and Lambert, P.F. 2013. Merkel cell polyomavirus: A newly discovered human virus with oncogenic potential. Virology. 435, 1 (Jan. 2013), 118–130. DOI:https://doi.org/10.1016/j.virol.2012.09.029.
[33]
Topalian, S.L. et al. 2012. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. New England Journal of Medicine. 366, 26 (Jun. 2012), 2443–2454. DOI:https://doi.org/10.1056/NEJMoa1200690.
[34]
Varghese, S. and Rabkin, S.D. 2002. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Therapy. 9, 12 (Dec. 2002), 967–978. DOI:https://doi.org/10.1038/sj.cgt.7700537.
[35]
Weinberg, R.A. 2014. The biology of cancer. Garland Science.
[36]
Weiss, R.A. and Vogt, P.K. 2011. 100 years of Rous sarcoma virus. The Journal of Experimental Medicine. 208, 12 (Nov. 2011), 2351–2355. DOI:https://doi.org/10.1084/jem.20112160.
[37]
Wendzicki, J.A. et al. 2015. Large T and small T antigens of Merkel cell polyomavirus. Current Opinion in Virology. 11, (Apr. 2015), 38–43. DOI:https://doi.org/10.1016/j.coviro.2015.01.009.